The results of the PURPOSE 2 trial released in September 2024, showed that 99.9% of the 2,180 cisgender men and gender-diverse participants in the United States, South Africa, Peru, Brazil, Argentina, ...
The collaboration supports efforts for HIV prevention through PrEP, emphasizing Hetero’s commitment to improving HIV care.
It is one of six global partners to have signed a voluntary licence agreement with Gilead to produce a high-quality generic ...
The Israeli military issued evacuation warnings for 20 more towns and villages in southern Lebanon, signaling a potential ...
International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company ...
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its ...
Surprise: Hannah and I switched Slog days. Because I respect tradition, we’ll begin with the weather, which is quite nice ...
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...
Ferozsons Laboratories Limited (Ferozsons), a Pakistani pharmaceutical company, has entered into a non-exclusive voluntary license agreement with Gilead Sciences Ireland UC, a US-based ...
Six drugmakers sign agreements with Gilead Sciences to produce generic lenacapavir, a long-acting HIV drug, amid patent ...
3 October 2024 (Geneva, Switzerland) – IAS – the International AIDS Society – applauds moves by Gilead Sciences to make generic injectable lenacapavir for HIV prevention widely available, but cautions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback